Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) shares traded down 5.6% during mid-day trading on Monday . The stock traded as low as $21.01 and last traded at $21.27. 68,622 shares were traded during mid-day trading, a decline of 64% from the average session volume of 190,155 shares. The stock had previously closed at $22.52.
Analyst Upgrades and Downgrades
Several research firms have weighed in on KMTS. Wells Fargo & Company began coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an "overweight" rating and a $28.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued a "buy" rating and a $28.00 price objective for the company. Bank of America began coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a "buy" rating and a $30.00 target price on the stock. The Goldman Sachs Group dropped their price target on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a research report on Wednesday, April 16th. Finally, Wolfe Research initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an "outperform" rating and a $29.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $27.50.
Check Out Our Latest Research Report on KMTS
Kestra Medical Technologies Stock Performance
The company's 50-day moving average is $23.24.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Monday, April 14th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter last year, the business posted ($1.18) EPS.
Institutional Trading of Kestra Medical Technologies
Several institutional investors and hedge funds have recently modified their holdings of KMTS. Yu Fan acquired a new position in Kestra Medical Technologies during the first quarter worth about $56,880,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Kestra Medical Technologies during the 1st quarter valued at approximately $56,613,000. Omega Fund Management LLC acquired a new position in Kestra Medical Technologies during the 1st quarter worth approximately $44,754,000. Alliancebernstein L.P. bought a new position in Kestra Medical Technologies in the 1st quarter valued at approximately $29,500,000. Finally, Brown Advisory Inc. acquired a new stake in Kestra Medical Technologies in the first quarter valued at approximately $13,716,000.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
